Simulations Plus, Inc. (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, highlighted its impact on the pharmaceutical industry through supporting the development of a majority of the drugs approved by the U.S. Food and Drug Administration (FDA) in 2024 .
“For more than 25 years, our clients have entrusted us to provide the mission-critical software and services needed to develop therapies that are changing the landscape of healthcare,” said Shawn O’Connor , Chief Executive Officer at Simulations Plus. “We are proud that our advanced modeling and simulation software and consulting services supported the development of the majority of drugs approved by the FDA in 2024. This achievement underscores the increasing role that innovative technologies and collaborative expertise plays in accelerating the drug development process. As global health challenges grow, we remain committed to delivering solutions which help advance life-saving therapies that improve patient outcomes worldwide.”
Simulations Plus offers software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. SLP’s suite of solutions leverage artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics/physiologically based biopharmaceutics (PBPK/PBBM), quantitative systems pharmacology/quantitative systems toxicology (QSP/QST), and population PK/PD modeling approaches, as well as adaptive learning and medical communications tools.
